OptimizeRx CorpOPRX
Price$8.39Intrinsic value$10.3924% above price

Valuation

How Intrinsic Value compares with model outputs

Intrinsic Value $10.39median of 6 methods · middle span $5-$13based on filings through 30 Jun 2026
Market Price $8.39Price as of 1 Oct 2026
Margin of Safety +23.8%as of 1 Oct 2026

Valuation methods vs. Market Price

Company vs. peer median Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up

Assumptions

ParameterValue
Years 1–5: analyst growth pathFive-year total matches analyst consensus exactly. Year 1: 5.0% (near-term consensus, capped) · years 2–5: 5.0%/yr (balance of the path).5.0% per year
Years 6–10: glide to demonstrated growth own history 46.0%, capped at 20%
Per-year rates
Yr 65.0%Yr 75.0%Yr 85.0%Yr 95.0%Yr 105.0%
5.0% → 5.0%
Years 11–20: glide to long-run rate
Per-year rates
Yr 114.8%Yr 124.6%Yr 134.4%Yr 144.2%Yr 154.0%Yr 163.8%Yr 173.6%Yr 183.4%Yr 193.2%Yr 203.0%
5.0% → 3.0%
Beyond year 20: terminal growthPerpetual long-run rate3.0%
Historical EPS growth (multi-year median)median of 1 window (7y) (limited history)46.0%
Discount rate (cost of equity) 9.6%
Volatility vs market (adjusted beta)1.03

Valuation Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up

Assumptions Sandbox Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up

Compare with peers

Search any company to compare valuation, profitability, returns, growth, and financial strength side by side.

Compare the target company plus 1 peer. Sign in / Sign up to compare a maximum of 3 peers.

Best in rowHigher is betterLower is better—Data not available
TargetOptimizeRx CorpOPRXHealth Care
Valuation
P/E33.6×
P/S1.3×
P/B1.1×
EV / Revenue1.2×
EV / EBITDA4.4×
Profitability
Gross margin75.2%
Operating margin2.0%
Net margin4.2%
FCF margin16.8%
Returns
ROE3.5%
ROA2.8%
ROIC3.7%
Growth
Revenue growth (YoY)18.8%
5-yr fwd EPS growth—
Financial strength
Debt / Equity0.15×
Current ratio5.58×
Altman Z-Score3.1
Interest coverage—
Dividend yield—

Best value in each row is highlighted. Figures are periodic snapshots from the same filings used across each dossier; a dash means the figure is not available.

AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.